About Centre for Pharmacoepidemiology
The Centre for Pharmacoepidemiology (CPE) works in a dynamic environment at the intersection of academia, healthcare, authorities and the pharmaceutical industry.
We conduct academic research on drug safety, drug effectiveness and drug utilization and perform regulator-mandated Post-Authorisation Safety Studies (PASS) and Drug Utilization Studies (DUS) in the area of pharmacoepidemiology.
Over the years, CPE has developed specific pharmacoepidemiological expertise in the following areas:
- Reproductive and Perinatal Pharmacoepidemiology
- Psychiatry and neurological diseases
- Chronic and inflammatory diseases
A large part of our research is based on data from the national registers at the National Board of Health and Welfare and Statistics Sweden, as well as corresponding registers from other countries, especially the Nordic countries. Data from quality registers and medical records are occasionally also included in our research.
We collaborate with several national and international research groups and are part of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP, https://www.encepp.eu/), the Nordic Network for Pharmacoepidemiology (NorPEN, https://www.norpen.org/ ) and the SIGMA consortium ( a contract-based alliance of ENCePP research centres, https://sigmaconsortium.eu/about-us/).
We also have a close collaboration with the Clinical Epidemiology Division (KEP) at the Department of Medicine and other research groups in epidemiology and pharmacology at Karolinska Institutet.